Sie befinden Sich nicht im Netzwerk der Universität Paderborn. Der Zugriff auf elektronische Ressourcen ist gegebenenfalls nur via VPN oder Shibboleth (DFN-AAI) möglich. mehr Informationen...
Prognostic impact of significant mitral regurgitation in patients with severe low flow, low gradient aortic stenosis undergoing transcatheter aortic valve replacement
Ist Teil von
European heart journal cardiovascular imaging, 2023-06, Vol.24 (Supplement_1)
Erscheinungsjahr
2023
Link zum Volltext
Quelle
Oxford Journals 2020 Medicine
Beschreibungen/Notizen
Abstract
Funding Acknowledgements
Type of funding sources: None.
Aim
The aim of this study was to determine the prevalence and prognostic implications of MR severity in patients with LFLG-AS undergoing TAVR, and to evaluate whether the improvement of MR after procedure could influence 1-year outcome.
Methods
All consecutive patients with severe LFLG-AS undergoing TAVR in two high-volume Italian centres from 2017 to 2022 were prospectively included. LFLG-AS was defined as indexed aortic valve area (AVAì) ≤0.6 cm2/m2; mean gradient <40 mmHg and stroke volume index <36 ml/m2. LFLG-AS was classified as classical if LVEF was <50%, and paradoxical if LVEF was >50%. Dobutamine stress-echo was systematically performed in patients with LVEF<50% in order or exclude pseudo-severe AS. The study population was divided into two groups according to the baseline MR severity: ≤2+ (moderate or less than moderate) and >2+ (moderately-severe or severe) and reassessed after TAVR. The primary outcome was the composite of all-cause death and hospitalization for HF up to 1 year. The secondary outcomes were the single components of the primary outcome.
Results
The study included 268 patients [81±6 years; 53% females]; of them, 57 (21.3%) patients showed MR>2+ at hospital admission. Patients with MR>2+ showed a significantly higher NYHA class at admission (p = 0.001); higher EuroSCORE II (p<0.001); lower LVEF at baseline (p = 0.003); higher RV dysfunction (p = 0.003) compared with those with MR≤2+. Death was reported in 2 (0.7%) patients, vascular complications in 8 (3%), and permanent pacemaker implantation in 23 (8.5%).
The primary outcome was reported in 55 (20.5%) patients; all-cause death was reported in 29 (10.8%) patients, and HF hospitalization in 34 (12.7%). At one year, patients with MR>2+ showed a significantly higher percentage of the primary outcome (p <0.001) and of all-cause mortality (p<0.001), which was related to cardiovascular cause in the majority of cases, and of HF rehospitalization (p<0.001). The survival free from the primary and secondary outcome was significantly lower in patients with MR>2+ compared with those with MR≤2+ (Log-Rank <0.001; Figure 1). The absence of MR improvement after TAVR was associated with higher percentage of the primary outcome (p = 0.020), all-cause death (p = 0.044), and HF rehospitalization (p = 0.030) at one year. The one-year survival free from the primary and secondary outcome was significantly higher in patients with MR improvement than in those without (Log-Rank = 0.009; Figure 2).
Conclusion
MR>2+ was reported in about 20% of patients with LFLG-AS undergoing TAVR, portend a worse clinical outcome up to one year. TAVR may improve MR severity, resulting in a potential outcome benefit after discharge. Our study suggests that both, the presence and the persistence of moderately-severe or severe MR, are of utmost importance for patient prognostic stratification, and should be carefully and systematically assessed in the very high-risk clinical scenario of LFLG-AS undergoing TAVR.